File: The Pfizer-BioNTech jab is one of several vaccine candidates approaching approval in a number of countries, bringing hope for an end to the pandemic. AFP/Joel Saget JOHANNESBURG - A study conducted in Israel suggests the Pfizer vaccine may be less effective against the COVID-19 variant first discovered in South Africa. But researchers caution that the study sampled a small number of people because of the rarity of the variant in Israel. READ: Pfizer to test third dose, tweaked vaccine to target variant first detected in SA The study compared almost 400 people who had tested positive for COVID-19. The B.1.351 variant was found to make up about 1 percent of COVID-19 cases across all the people studied. READ: Study: Pfizer jab protects against variant Among patients who received two doses of the vaccine, the variant’s prevalence rate was eight times higher than those unvaccinated. South Africa has recently ordered around 20 million doses of the Pfizer vaccine.